IP Library Granted Patent US 9,181,332
Granted Patent B2
US 9,181,332 · App. 13/678,214 · Granted Nov 10, 2015

Anti-A(β) oligomer humanized antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,332
App. No.
13/678,214
Granted
Nov 10, 2015
Kind
B2
Abstract

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Claims (4)

1. A DNA which encodes a variable region of an antibody or an antibody fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12 or 15 or the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 14, 16 or 17.

2. A recombinant vector which comprises the DNA according to claim 1 .

3. A transformant obtainable by introducing the recombinant vector according to claim 2 into a host cell.

4. A process for producing an antibody or antibody fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ NO: 12 or 15 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 14, 16 or 17, comprising culturing the transformant described in claim 3 in a medium to form and accumulate the antibody or the antibody fragment thereof, wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12 or 15 and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 14, 16 or 17 in the culture and collecting the antibody or the antibody fragment thereof from the culture.

Assignments (3)
MERGER Recorded Mar 26, 2025
From: IMMUNAS PHARMA, INC.
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 070641/0569 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 2, 2024
From: KYOWA KIRIN CO., LTD.
To: IMMUNAS PHARMA, INC.
Reel/Frame 065998/0142 →
CHANGE OF NAME AND ADDRESS Recorded Oct 23, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050797/0533 →